Relationship of blood and bone lead to menopause and bone mineral density among middle-age women in Mexico City. by Garrido Latorre, Francisco et al.
For decades the population of Mexico City
was exposed to high environmental lead lev-
els because of the combustion of leaded
gasoline and poor environmental control of
industrial activities. However, this situation
changed in 1986 with regulatory actions
that reduced the lead emissions and lead
content of gasoline, culminating in its elimi-
nation in 1997 (Hernández-Avila et al.
2000). Similar regulatory actions were estab-
lished for other sources of lead exposure such
as paints, solders in canned food, and cos-
metics. In addition, in 1995 the Mexican
government initiated the search for alterna-
tive substitute for lead used in low-tempera-
ture hand-made ceramics, but at present this
type of ceramic remains the main non-
occupational source of lead exposure in
Mexico (Hernández-Avila and Romieu 1991;
Romieu et al. 1994).
Lead from environmental and occupa-
tional sources enters the body through inhala-
tion of particles or intake of lead-contaminated
food (Lockitch 1993). It is transported by
blood to soft tissues, where it remains for short
periods and is ﬁnally deposited in bone tissue
(Barry and Mossmann 1970). More than 90%
of the lead present in the body is stored in
bones throughout life, where it may remain for
decades (Barry and Mossmann 1970).
Nevertheless, bone tissue does not represent a
site of permanent sequestration of lead but
rather a source of continuous internal exposure
that may increase as a result of the changes in
bone turnover observed at different life stages
(Gulson et al. 1995; Pounds et al. 1991). This
may be the case with menopause, where bone
mass loss is a frequent phenomenon that typi-
cally starts in the perimenopausal years and
continues with an accelerated loss in the early
postmenopausal years (Cummings et al. 1985;
Elders et al. 1988; Nilas and Christiansen
1988; Riggs and Melton 1986; Ruegsegger et
al. 1984; Silbergeld et al. 1993).
Although previous studies demonstrated
the blood lead increase during this stage of
life (Muldoon et al. 1994; Silbergeld et al.
1988; Symansky and Hertz-Picciotto 1995;
Weyerman and Brenner 1998), only one
study recently published simultaneously
measured lead levels in blood and bone
among perimenopausal women (Korrick 
et al. 2002).
The objective of this study was to examine
the relationship between blood and bone lead
during menopause under the hypothesis that
postmenopausal (PosM) women have higher
blood lead levels in comparison with pre-
menopausal women after controlling for bone
lead content, age, and exposure to environ-
mental sources. A second hypothesis is that
higher bone remodeling rates among PosM
women—using bone mineral density (BMD)
as an indicator—is associated with higher
blood lead levels after controlling for age and
bone lead among other variables.
Materials and Methods
The study population was recruited from
women attending an osteoporosis-screening
program carried out by the Mexican
Committee for Osteoporosis Research in
Mexico City. Women were recruited through
conferences given live during a radio program
aimed at women. During the program, one of
us (J.T.O.), an expert in osteoporosis,
explained to the audience a set of actions to
prevent osteoporosis and provided informa-
tion regarding its diagnosis and treatment
and the screening program. The radio pro-
grams were broadcast during the ﬁrst quarter
of 1995, and a total of 961 women were
recruited. Once the clinical procedures neces-
sary for osteoporosis diagnosing were carried
out, all participants were invited for compli-
mentary measurements of blood and bone
lead levels. A total of 653 women consented
to the blood lead test, and 35% of these (n =
232) completed measurements of both blood
and bone lead. The primary reason for not
completing the bone lead measurement was
the inconvenience of particiants visiting a dif-
ferent clinic far from the initial enrollment
and screening center. For the analyses, the
final sample was made up of these 232
women, of whom 36 were pre- or peri-
menopausal (PreM) and 196 were PosM.
The research protocol was approved by
the Human Subjects Committee of the
National Institute of Public Health of
Mexico. All participants gave their informed
consent and received a detailed explanation of
the study and procedures used, as well as
counseling on how to reduce lead exposure.
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To describe the relationship of blood lead levels to menopause and bone lead levels, we conducted
a cross-sectional study on 232 pre- or perimenopausal (PreM) and postmenopausal (PosM)
women who participated in an osteoporosis-screening program in Mexico City during the first
quarter of 1995. Information regarding reproductive characteristics and known risk factors for
blood lead was obtained using a standard questionnaire by direct interview. The mean age of the
population was 54.7 years (SD = 9.8), with a mean blood lead level of 9.2 µg/dL (SD = 4.7/dL)
and a range from 2.1 to 32.1µg/dL. After adjusting for age and bone lead levels, the mean blood
lead level was 1.98 µg/dL higher in PosM women than in PreM women (p = 0.024). The increase
in mean blood lead levels peaked during the second year of amenorrhea with a level (10.35 µg/dL)
that was 3.51 µg/dL higher than that of PreM women. Other important predictors of blood lead
levels were use of lead-glazed ceramics, schooling, trabecular bone lead, body mass index, time of
living in Mexico City, and use of hormone replacement therapy. Bone density was not associated
with blood lead levels. These results support the hypothesis that release of bone lead stores
increases during menopause and constitutes an internal source of exposure possibly associated
with health effects in women in menopause transition. Key words: blood lead, bone lead, bone
mineral density, menopause, Mexico. Environ Health Perspect 111:631–636 (2003).
doi:10.1289/ehp.5149 available via http://dx.doi.org/ [Online 16 December 2002]
Environmental Medicine | ArticlesWe used a structured questionnaire that
collected information on sociodemographics,
life styles, reproductive history, and sources of
environmental exposure to lead. The education
level of the subjects was grouped in the follow-
ing three categories: less than primary school,
primary and secondary school, and high school
or more. We also asked about tobacco con-
sumption, alcohol consumption, and physical
exercise. With regard to tobacco, the subjects
were classified according to current smoking
habits. Alcohol consumption was analyzed
according to frequency (abstainers, less then
once a month but at least once a year, from
two to three times a month, and one or more
times a week) and the number of drinks con-
sumed per occasion. Regarding physical activ-
ity, participants were asked whether they
currently exercised on a regular basis. In the
section of reproductive characteristics, we col-
lected information on the use of exogenous
hormones and the time of their use, either for
family planning purposes or to treat symptoms
associated with menopause. Other variables
included the number of pregnancies overall,
the number of deliveries, total period of breast-
feeding (in months), type of menopause (nat-
ural or surgical), and years since menopause.
Women were classified as menopausal
according to their answers to the following
questions: Do you continue menstruating
(yes/no)? If you have stopped menstruating,
how long have you not been menstruating
(number of months)? Have you stopped men-
struating in the natural way, because of some
disease, pregnancy or lactation, or because
you underwent surgery? The menopause
event was considered positive when the sub-
jects were in amenorrhea for 12 months not
due to pregnancy, lactation, or any disease or
surgical procedure. Finally, menopause was
classified as natural or surgical. Years since
menopause was calculated as the time since
the last menstrual period or time since hys-
terectomy. The questionnaire also included a
section to identify sources of environmental
and indoor exposure to lead. Among them,
the following were identiﬁed: type of vehicu-
lar traffic next to the place of residence
(intense, intermediate, or low), residence time
(in years) in Mexico City, and overall time
spent in preparing and storing food in lead-
glazed ceramics. These characteristics 
represent the most important sources of lead
exposure previously identiﬁed in our popula-
tion (Hernández-Avila and Romieu 1991;
Romieu et al. 1994).
Lead measurements. Blood samples were
analyzed with a graphite furnace atomic
absorption spectrophotometry instrument
(Perkin Elmer 3000; Perkin Elmer, Norwalk,
CT) at the metals laboratory of the American
British Cowdray Hospital in Mexico City.
The laboratory standardization program of
the Wisconsin State Laboratory of Hygiene
(Madison, WI) provided external quality con-
trol specimens varying from 2 to 88 µg/dL.
Our laboratory maintained acceptable preci-
sion and accuracy during the study time (cor-
relation = 0.98; mean difference, 0.71 µg/dL;
SD = 0.68).
Bone lead measurements were taken of each
subject’s midtibial shaft (cortical bone) and
patella (trabecular) using a spot-source 109Cd
KXRF instrument constructed at Harvard
University and installed in a research facility at
the American British Cowdray Hospital.
Physical principles, technical specifications, 
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Table 1. Characteristics of women participating in
the study according to their distribution in partici-
pation groups.
Participated 
in the bone lead
screening test
Variables Yes No p-Value
Age (years)
n 232 421
Mean 54.1 53.3 0.33
Blood lead (µg/dL log-e)
n 232 421
Mean 9.2 10.0 0.004
Height (cm)
n 222 406
Mean 154.7 153.9 0.09
Weight (kg)
n 222 406
Mean 64.5 62.2 0.01
Lumbar spine (µg/cm2)
n 221 405
Mean 1.022 1.035 0.64
Femoral neck (µg/cm2)
n 220 402
Mean 0.873 0.881 0.46
No. of pregnancies
n 232 421
Mean 4.2 4.1 0.53
Use of lead-glazed ceramics
Yes 49 99
No 183 322 0.48
Literacy (years of school)
0–5 27 54
6–9 154 267
≥ 10 51 99 0.51
Smoking (%)
Yes (current) 42 64
Yes (past) 45 62 0.58
Never 145 278
Table 2. Study population according to selected variables.
Percentages or means
Variables na and SD values Range
Age (years) 232 54.1 ± 9.8 28–88
Literacy (%)
0–5 years 27 11.6
6–9 years 154 66.4
≥ 10 years 51 22.0
Height (cm)  222 154.7 ± 5.8 1.43–1.82
Weight (kg) 222 64.5 ± 10.9 44–105
Body mass index 222 27.1 ± 4.6 17.3–35.8
Blood lead (µg/dL) 232 9.2 ± 4.7 2.1–32.1
Patella lead (µg Pb/g bone mineral) 232 22.73 ± 14.9 ND–89.3
Tibia lead (µg Pb/g bone mineral) 232 14.85 ± 10.1 ND–57.8
Smoking (%)
Yes (current) 42 18.1
Yes (past) 45 19.3
Never 145 62.6
Physical activity (%)
Yes 128 55.2
No 104 44.8
No. of drinks per week (%)
One or less 127 54.7
Two 55 23.7
Three or more 50 21.6
Use of lead-glazed ceramics
Yes 49 21.1
No 183 78.8
Menarche (mean age) 232 12.7 ± 1.5 9–17
No. of pregnancies 232 4.26 ± 2.6 0–13
History of breast-feeding (%)
Yes 187 80.6
No 26 11.2
Nulliparous 19 8.2
Premenopausal or perimenopausal 36 15.5
Postmenopausal 196 84.5
Surgical 76 32.8
Natural 120 51.7
Age at menopause 196 45.3 ± 7.0 24–60
Years since menopause 191 11.3 ± 8.7 1–42
BMD lumbar spine (g/cm2) 221 1.022 ± 0.18 0.47–1.62
BMD femoral neck (g/cm2) 220 0.873 ± 0.14 0.54–1.31
aSome variables have missing values.validation, and use of this and other KXRF
instruments have been described in detail else-
where (Aro et al. 1994; Hu et al. 1995).
In brief, the instrument uses a 109Cd γ-ray
source to provoke the emission of ﬂuorescent
photons from target tissue that are then
detected, counted, and arrayed on a spectrum.
Net lead signal is determined after subtraction
of Compton background counts by a linear
least-squares algorithm. The lead ﬂuorescent
signal is then normalized to the elastic or
coherently scattered γ-ray signal, which arises
predominantly from the calcium and phos-
phor present in bone mineral. For the present
study, 30-min measurements were taken at
the midshaft of the left tibia (cortical bone)
and at the left patella (trabecular bone) after
each region had been washed with a 50%
solution of isopropyl alcohol. The instrument
provides an estimate of the uncertainty associ-
ated with each measurement; for purposes of
quality control of bone lead measurements,
we excluded 14 individuals with questionable
values either because the movement of the
limb being measured was out of the measure-
ment ﬁeld or because of the extreme thickness
of overlying tissue, which resulted in estimates
of uncertainty greater than 10 µg Pb/g bone
mineral for the tibia or 15 µg Pb/g for the
patella. The mean uncertainty (and SD) for
patella and tibia in our study were 8.4 (2.8)
and 6.9 (3.1), respectively.
BMD was measured at the lumbar spine
and femur neck with a LUNAR DEXA (dual
energy x-ray absorptiometry) densitometer
(GE Lunar Corp., Madison, WI). On initiat-
ing each measuring session, the equipment
was calibrated by standardized mineral density
devices (photons) whose coefﬁcients of varia-
tion were lower than 4%. The results are
expressed in grams per square centimeter. We
used the criteria established by the World
Health Organization (WHO 1994) for
BMD classiﬁcation: a) normal, if BMD value
was greater than at least 1 SD in relation to
the reference group; b) osteopenia, if BMD
was between –1.0 and –1.5 SD values; and 
c) osteoporosis, if BMD was lower than 
–2.5 SD values in relation to the reference
group (WHO 1994).
We performed an exploratory analysis of
each variable included in the study by univari-
ate statistics and distribution plots. The bivari-
ate analysis included test (two groups) and
analysis of variance (three or more groups);
linear regression models were used to examine
the relationship between blood lead levels and
variables of interest. The age effect was mod-
eled using linear and quadratic terms to
account for nonlinear relationships observed
between age and blood lead (Hernández-Avila
et al. 2000; Silbergeld et al. 1988).
First, the relationship between each 
variable and log-e (natural log) transformation
of blood lead levels was examined. Then, we
analyzed the relationship between blood lead
and all those variables that in bivariate analysis
would have achieved 0.15 significance level.
We defined the best model by dropping
covariates one by one from a saturated model
that included all variables with a p-value below
0.15. Our final multivariate model included
all-important predictors with a statistically sig-
niﬁcant association deﬁned at p < 0.10.
When bone lead concentrations are very
low (< 5 µg/g bone mineral), the K-XRF
measurements may provide negative values
because of the algorithm used by equipment
software (Hu et al. 1995). To test the robust-
ness of our ﬁndings in relation to negative val-
ues, these were randomly distributed within
an interval between 0 and 5 µg Pb/g of bone
mineral. Reanalysis using these values did not
change the estimates of interest. All statistical
analysis procedures were carried out with a
Stata package (Stata Statistical Software,
release 7.0, Stata Corp., College Station, TX).
Results
The study group (n = 232) showed no 
differences in relation to nonparticipants
regarding most characteristics of interest
(Table 1). Women who participated showed a
lower mean blood lead concentration and a
higher body weight.
The group of PreM women constituted
15.5% of the total population. The age of the
population ranged from 28 to 88 years, with a
mean of 54.7 years (SD = 9.8). Most of these
women (66.4%) had an intermediate level of
schooling (6–9 years). Regarding reproductive
characteristics, 92% had a history of one or
more pregnancies (mean 4.3, SD = 2.6), and
81% had breast-fed their infant. The mean
age of natural menopause was 47.6 years 
(SD = 5.8) and of surgical menopause was
42.2 years (SD = 6.7). About 46% of the par-
ticipants with menopause reported the use of
hormone replacement therapy (HRT).
Life-style characteristics were as follows:
18% of the participants were classiﬁed as cur-
rent smokers; 55% exercised on a regular
basis; 22% consumed three or more alcoholic
drinks per occasion, and 23% prepared meals
in lead-glazed ceramic cookware during the
last week. Blood lead levels were distributed
between a minimum value of 2.1 µg/dL and a
maximum of 32.1 µg/dL, with a mean of 9.2
µg/dL (SD = 4.71) and a 95% confidence
interval of 8.5–9.8 µg/dL. Lead values in tra-
becular and cortical bone were distributed
with means of 22.7 µg Pb/g of bone mineral
(SD = 14.9) and 14.9 µg Pb/g (SD = 10.09),
respectively (Table 2). Lead levels in trabecu-
lar bone (patella) explained an important per-
centage of blood lead variation (r2 = 18%).
For each 1 µg Pb/g of bone mineral, blood
lead levels increased by 1.1% (regression co-
efficient 0.011; p = 0.001). However, this
association varied significantly (p < 0.01)
when we stratified according to type of
menopause (Figure 1). Blood lead increased
by 0.3 and 1.1% per µg Pb/g of bone min-
eral, for PreM and PosM women, respec-
tively. According to this model, a change of
10 µg Pb/g of bone mineral in PosM will be
associated with an increase in blood lead of
1.4 µg/dL, whereas a similar change among
PreM women will be associated with an
increase of 0.8 µg/dL.
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Figure 1. Regression analysis between blood lead levels (micrograms per deciliter, log-e transformed) and patella
bone lead levels (µg Pb/g bone mineral) for all participants and subgroups divided according to menopausal status.BMDs of lumbar spine and femur neck
were distributed with means of 1.022
µg/cm2(SD = 0.177) and 0.873 µg/cm2
(SD = 0.135), respectively. We did not find
any relationship between blood lead values
and BMDs of lumbar spine and femur neck.
Regression coefficient for BMD of lumbar
spine was 0.0048 (p = 0.962), and for femur
neck was 0.1561 (p = 0.217). These coeffi-
cients were not modified after adjusting for
age and bone lead.
No linear relationship was observed
between blood lead levels and age (p = 0.23).
The highest mean blood lead was observed
for the 45- to 49-year-old group, correspond-
ing to the mean age of natural menopause,
when it reached a mean concentration of 10.6
µg/dL and progressively decreased to values
smaller than those found in PreM women.
In the baseline multivariate model that
adjusted for age and bone lead (Table 3),
PosM women showed blood lead levels 1.98
µg/dL higher than those found in PreM
women (p = 0.024). This increase was appar-
ent for women with surgical menopause
(1.91 µg/dL) and women with natural
menopause (2.1 µg/dL) compared with that
for PreM women. In relation to the years
since menopause, the distribution of blood
lead values showed two points of inflection
that, in the case of women with surgical
menopause, corresponded to the first and
ﬁfth year after menopause (11.17 and 10.07
µg/dL), which corresponded to a difference
of 3.35 and 1.92 µg/dL compared with those
in the PreM group (p = 0.158); for women
with natural menopause, the two points of
inflection corresponded to the second and
fourth year after menopause (10.35 and
11.43 µg/dL), differences of 2.2 and 3.28
µg/dL, respectively (p = 0.063).
PosM women who used HRT (adjusting
for age and bone lead) had lower blood lead
levels than PosM women who did not use the
therapy, with an estimated mean blood lead
difference of –1.25 µg/dL (p = 0.09). When
the analysis was restricted to the group of par-
ticipants with natural menopause, the mean
blood lead concentration was 2.64 µg/dL
higher in the group of PosM women who
were nonusers of replacement estrogens 
(p = 0.005).
The use of lead-glazed ceramics was an
important predictor of blood lead levels. The
women who prepared and stored food in
lead-glazed ceramic cookware during the
previous week showed higher blood lead
compared with those who did not use it,
with differences of 2.48 and 2.01 µg/dL,
respectively (p < 0.05).
Finally, the most parsimonious multivariate
model that explained 38.7% of the variation in
blood lead levels included the following vari-
ables: age (linear and quadratic terms), time of
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Table 3. Blood lead levels (microgram/deciliter) according to sociodemographic, life style, and reproduc-
tive characteristics. 
Means adjusted 
by age and  Adjusted
Variables n Mean SD p-Valuea bone lead p-valuea
Age groups (years)
< 40  12 10.5 5.5 0.23 9.7 0.19
40–44 23 9.4 4.1 9.1
45–49 41 10.6 6.0 10.4
50–54 40 9.1 3.9 9.2
55–59 49 8.5 3.0 9.1
60–64 30 8.9 5.5 8.8
65–69 19 8.3 6.4 8.4
≥ 70 18 7.7 3.2 7.5
Literacy (years of school)
0–5 27 10.2 5.7 0.06 10.9 <  0.01
6–9 154 9.3 4.7 9.2
≥ 10 51 8.1 4.1 8.1
No. of pregnancies
None 19 9.7 5.7 0.42 9.8 0.24
1–3 82 8.5 3.2 8.4
4–6 87 9.0 4.4 9.1
≥ 74 4 10.4 6.7 10.4
Breast-feeding
No 26 8.2 3.2 0.43 8.26 0.38
Yes 187 9.2 4.8 9.21
Menopause
No (PreM) 36 9.4 4.9 0.69 7.5 0.02
Yes (PosM) 196 9.1 4.7 9.5
Type of menopause
PreM 36 9.4 4.9 0.50 7.4 0.08
Surgical 76 9.3 3.8 9.4
Natural 120 9.00 5.2 9.5
Time since menopause (surgical, months)
PreM 36 9.4 4.9 0.32 8.2 0.15
12 9 11.2 4.5 11.2
13–24 6 11.1 3.9 9.9
25–36 10 7.5 2.7 8.2
37–48 9 8.9 3.6 9.3
≥ 49 years 42 9.1 3.7 10.1
Time since menopause (natural, months)
PreM 36 9.4 4.9 0.23 6.8 0.06
12 15 9.3 4.3 7.9
13–24 18 9.7 4.5 10.4
25–36 12 6.8 2.5 7.2
37–48 12 11.2 7.2 11.4
≥ 49 years 58 8.9 5.6 10.3
HRT 
Yes 91 8.5 3.5 0.20 8.8 0.10
No 105 9.7 5.5 10.1
HRT (natural menopause)
Yes 53 7.5 3.1 < 0.01 8.4 0.01
No 67 10.2 6.1 10.5
HRT (surgical menopause )
Yes 38 9.8 3.7 0.14 9.4 0.41
No 38 8.7 3.1 9.1
Smoking 
Yes (current) 42 9.1 4.9 0.74 8.3 0.10
Yes (past) 45 8.0 4.8 8.4
Never 145 9.5 4.6 9.4
Physical activity 
Yes 128 9.6 5.2 0.09 9.5 0.14
No 104 8.6 3.9 8.6
No. of drinks 
One or less 127 8.7 4.7 0.112 8.9 0.20
Two 55 9.9 5.6 9.9
Three + 50 9.4 3.6 8.9
Use of lead-glazed ceramics
Yes 49 10.7 6.7 < 0.01 10.5 < 0.01
No 183 8.6 3.6 9.2
ap-Value from ANOVA using log-e transformed blood lead as the dependent variable. postmenopause, body mass index, patella lead,
use of lead-glazed ceramic cookware, schooling
level greater than 6 years, and time of living in
Mexico City (Table 4).
Discussion
Our results showed that blood lead increases
signiﬁcantly in the PosM period and particu-
larly in the first 3 years of this period. Our
data suggest that once these maximum levels
are achieved, the blood lead decreases in the
third year and afterward starts increasing
again. This ﬁnding is consistent with a partic-
ular bone remodeling pattern during the ﬁrst
years of postmenopause that mainly depends
on higher bone turnover of trabecular bone.
As is well known, the trabecular bone loss
increases in the perimenopausal period, which
is followed by an accelerated loss in the first
years of postmenopause, and then bone
resorption decreases and becomes constant
(Cummings et al. 1985; Elders et al. 1988;
Nilas and Christiansen 1988; Riggs and
Melton 1986; Ruegsegger et al. 1984).
As reported by Muldoon et al. (1994),
our study did not ﬁnd high blood lead levels
in women with low mineral density.
Measurements of BMD in cross-sectional
studies provide a snapshot of the balance
between bone deposition and bone resorption
rates over preceding years, whereas blood lead
levels would be expected to depend more
speciﬁcally on absolute rates of ongoing bone
resorption. Because of this limitation Hu 
et al. (1998) proposed the use of bone mark-
ers that are speciﬁc for ongoing rates of bone
resorption such as the N-telopeptide of type I
collagen (urinary NTX). Recent research in
elderly men suggests that urinary NTX is a
significant modifier of the bone lead–blood
lead relationship.
The age-adjusted difference in trabecular
bone lead concentrations observed between
PosM and premenopausal women (difference
of –5.8 µg of lead per gram of bone mineral; 
p = 0.02) supports the hypothesis that the lead
is mobilized from the bone compartments
toward the circulation and contributes to the
increase of blood lead levels in this stage of life.
The hypothesis is also supported by our 
observation that the use of replacement estro-
gens was also associated with lower blood lead
levels among PosM women. Furthermore,
patella lead explained the greatest part of varia-
tions in blood lead levels, and its independent
effect remained the same after controlling other
important predictors of blood lead. A different
pattern was found in the association between
tibia lead and blood lead. These levels were
marginally different between PreM and PosM
women (p = 0.06). This difference suggests the
existence of lead pools in the mineral tissue (tra-
becular represented by patella and cortical by
tibia) that follow different turnovers. In cortical
bone, it is known that its turnover is much
slower than that occurring in trabecular bone,
so its contribution to blood lead levels is
expected to be smaller. It should be noted,
however, that cortical bone composes the
majority of skeletal mass (~80%), making even
modest resorption of cortical bone a potentially
major inﬂuence on blood lead levels. Similar
results were reported by Kosnett et al. (1994) in
women older than 55 years. Silbergeld et al.
(1988) and Symansky and Hertz-Picciotto
(1995) observed an increase of blood lead in
nulliparous PosM women after comparing
them with multiparous women. This ﬁnding
suggests that pregnancy, and probably breast-
feeding as well, may mobilize the lead deposited
in bone simultaneously with calcium, to meet
the calcium requirements observed in preg-
nancy and lactation, leaving smaller amounts of
lead to be mobilized during the menopause
transition. These results have not been con-
firmed by other investigators (Brown et al.
2000; Muldoon et al. 1994; Weyerman and
Brenner 1998). In our study PosM women
who breast-fed had higher bone lead levels
(21.2 and 18.1 µg of lead per gram of bone
mineral; p = 0.23). These results are similar to
those reported by Brown et al. (2000) and
probably reflect the fact that this cohort of
women breast-fed during the years of high lead
concentrations in the Mexico City air and thus
incorporated additional lead during the bone
gain phase that is known to follow pregnancy
and lactation (Kalkwarf et al 1997).
HRT, alone or combined, prevents bone
resorption and increases the BMD in trabecu-
lar and cortical bones of women with and
without metabolic bone disease (Berlin et al.
1995; Gruber et al. 1997; Webber et al.
1995). This effect may lead to a decrease of
lead mobilization from bone together with a
reduction in blood lead levels. Webber et al.
(1995) reported that women with HRT
showed greater bone lead concentrations, espe-
cially in cortical bone, without having a simul-
taneous decrease in blood lead. In our study,
46.4% of the PosM women used HRT, and
the blood lead levels observed among them
were lower than those in nonusers (difference
of 2.1 µg/dL; p < 0.05). In addition, we
found that trabecular and cortical bone lead
levels were higher in women who used HRT
(1.19 and 0.43 µg Pb/g of bone mineral for
patella and tibia, respectively). This observa-
tion supports the hypothesis that HRT
reduces bone resorption, and by preventing
lead mobilization from bone and diminishing
blood lead levels, HRT may be considered a
preventive measure in PosM women with
high bone lead levels.
Compared with women of child-bearing
age living in Mexico City (Brown et al. 2000)
as well as perimenopausal women living in the
United States (Korrick et al. 2002), the mean
bone lead levels seen in these women were sig-
niﬁcantly higher. This ﬁnding reﬂects the fact
that women participating in our study were
living in Mexico City during the time that
gasoline had a higher lead content and thus
were subject to higher environmental lead
exposures in the recent past. The adjusted
regression coefﬁcient of patella bone lead on
blood lead predicted an increase of 0.80 µg
blood lead/µg bone lead for women of child-
bearing age and of 0.050 µg blood lead/µg
bone lead for perimenopausal women, which
were lower than estimated in this study (blood
lead 0.135 µg/µg of bone lead).
Our study has potential limitations that
may affect the inferences derived from these
data. The participants were primarily low- and
middle-class women who voluntarily attended
an osteoporosis program and were not a ran-
dom sample of the general population. Thus,
our results cannot be generalized to all women
living in Mexico City. Of note, we found dif-
ferences, in terms of both blood lead levels and
height, between women attending the screen-
ing program and women taking part in bone
lead measurements. However, the differences
observed in blood lead levels decreased once we
adjusted for other variables such as use of
ceramics, age, and menopausal status; there-
fore, it is unlikely that selection bias could
explain our ﬁndings. We used simple question-
naire data to characterize environmental expo-
sure to lead-glazed ceramic ware and thus may
have underestimated the contribution to blood
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Table 4. Results from multivariate linear regression of blood lead levels (log-e, microgram per deciliter) on
selected predictors of study participants
Variable Coefﬁcient p-Value 95% CI
Age linear (years) –0.063 0.01 –0.113 to –0.013
Age squared (years2) 0.0005 0.04 0.0001 to 0.001
Patella lead (µg Pb/g mineral bone) 0.012 < 0.01 0.008 to 0.015
Time postmenopausal (1–24 months)a 0.284 < 0.01 0.111 to 0.456
Time postmenopausal (≥ 25 months)a 0.204 0.03 0.020 to 0.388
Body mass index (kg/height in m)2 0.015 0.03 0.001 to 0.029
Keeps food in lead-glazed ceramics 0.221 < 0.01 0.100 to 0.342
Education level (6–9 years)b –0.191 0.040 –0.373 to –0.009
Education level (≥ 10 years)b –0.296 < 0.01 –0.506 to –0.085
Time living in Mexico City (years) 0.007 < 0.01 0.003 to 0.012
Constant 3.41 < 0.01 2.03 to 4.784
aYears since menopause is in reference to PreM. bEducational level of 0–5 years is the reference category.lead levels of this major known source of envi-
ronmental lead exposure in Mexico. Only 16%
of our study group (n = 36) were pre-
menopausal, limiting our ability to conduct a
more in-depth analysis of potential interactions
such as the potential modifying effect of
menopausal status on other factors that deter-
mined blood or bone lead levels. The cross-sec-
tional nature of these data also limited our
ability to do more sophisticated kinetic model-
ing of bone lead–blood lead interrelationships.
Suspicion exists that the accumulation of
lead in bone itself represents a risk factor for
osteoporosis. Individual cases such as the sub-
jects reported by Berlin et al. (1995) who had
occupational lead exposure, a bone fracture,
and diagnosis of idiopathic osteoporosis provide
some circumstantial evidence of such a relation-
ship. Other evidence supporting the hypothesis
that lead can directly damage bone includes
observations of fetal and neonatal growth
reduction and the development of osteopenia in
experimental animals exposed to lead (Gruber
et al. 1997). Pounds et al. (1991) reported that
bone cells, both in vitro and in vivo, may be
impaired by the presence of lead. However,
additional studies are required to directly assess
this hypothesis and to investigate indirect routes
by which lead may be related to osteoporosis,
such as the possibility that lead affects calcium
absorption at the level of the digestive tract or
that lead reduces circulating levels of 1,25-
dehydrocholecalciferol, as has been noted in
children by Mahaffey et al. (1982).
The increase in blood lead concentrations
that result from bone resorption after
menopause may, in turn, be associated with
health effects that have not been adequately
studied in elderly women. Studies of subjects
in other age groups show that relatively 
modest exposures to lead are associated with 
neurologic dysfunction, behavioral disorders,
hypertension, renal damage, and hematologic
changes (Vig and Hu 2000). It may be partic-
ularly important to study the relationship
between blood and bone lead levels and cog-
nitive impairment in perimenopausal women
because of the potential modifying role played
by osteoporosis in these women.
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